The alternative nuclear factor-kappaB (NF-kB) -activation pathway proceeds via inducible p100 processing, leading to the activation of RelB-containing dimers. This pathway is aberrantly activated in several types of tumors; however, a direct role for RelB in the control of cell proliferation is still largely unexplored. Here, we demonstrate that RelB provides cell proliferation-inhibitory signals in murine fibroblasts. In agreement with these results, RelB ectopic expression inhibits xenograft tumor growth in vivo, whereas RelB knockdown enhances it. Significantly, we show that RelB inhibits cell proliferation and tumor growth in a p53-dependent manner. Mechanistic studies indicate that RelB regulates the transcription of the p53 tumor-suppressor gene through direct recruitment to the p53 promoter, thus increasing both p53 protein levels and expression of p53 target genes such as p21. Our findings define a novel link between NF-kB and growth-inhibitory pathways involving the RelB-dependent transcriptional upregulation of p53. Furthermore, they suggest that inhibition of RelB in some tumor types that retain wild-type p53 may diminish rather than improve therapeutic responses.
INTRODUCTION
In mammals, the nuclear factor-kappaB (NF-kB) transcription factor family is composed of five members, RelA (p65), RelB, cRel (Rel), NF-kB1 (p50 and its precursor p105) and NF-kB2 (p52 and its precursor p100), and forms a collection of various homodimeric and heterodimeric complexes.
1,2 NF-kB activation is generally associated with cell survival and proliferation through the induction of anti-apoptotic and pro-proliferative proteins. 3, 4 Aberrant NF-kB activity has been observed in many cancers, including both solid and hematopoietic malignancies, and sustained activation of NF-kB can affect all six hallmarks of cancer including insensitivity to growth-inhibitory signals, evasion of apoptosis, induction of angiogenesis and metastasis, [5] [6] [7] leading to the concept of NF-kB addiction in cancer cells. However, this general view is increasingly challenged by recent evidence indicating that NF-kB can, under some circumstances, mediate pro-apoptotic effect, growth arrest and inhibition of cancer development. [8] [9] [10] [11] [12] [13] Therefore, an understanding of how NF-kB arbitrates these opposing outcomes has to be addressed before NF-kB-based therapy can become successful. Multiple mechanisms have been delineated to achieve the required specificity and selectivity of the NF-kB response, including regulation of specific target genes by individual NF-kB subunits 14 and crosstalk between NF-kB and other transcription factors, such as p53, 2, [15] [16] [17] but their influence on cell fate remains poorly understood.
Analysis of RelB-deficient mice has shown that RelB is essential for the development of medullary epithelium, mature dendritic cell function and secondary lymphoid organ organization. 18, 19 RelB À / À mice also spontaneously develop a multiorgan inflammatory syndrome that contributes to their premature mortality, 19 preventing long-term studies on cancer development. Thus far, the majority of evidence indicating growth-regulatory roles for RelB comes from gain-or loss-offunction mutations of molecules important for its activation in B-cell lymphoma cell lines and patient samples. 20, 21 In contrast, although there are indications suggesting that RelB may participate in tumor incidence and invasive phenotype, 22, 23 how RelB affects cell growth and tumor promotion in non-lymphoid cells is still debatable.
The p53 tumor suppressor is frequently mutated in human cancers. Like NF-kB, p53 has also been extensively implicated in the regulation of cell growth and involved in the pathogenesis of most, if not all, cancers. 24, 25 In its wild-type (WT) form, p53 exerts potent anti-tumor effects through the regulation of genes involved in growth arrest or induction of apoptosis. 24, 25 The crosstalk between NF-kB and p53 is becoming increasingly appreciated as an important mechanism that influences the intricate regulation of cell proliferation and survival of both normal and transformed cells, 17, 26, 27 but the potential participation of RelB remains unexplored.
In the study presented here, we reveal a role for RelB in limiting cell proliferation and tumor growth. We find that the p53 tumorsuppressor gene is a direct target of RelB in fibroblasts, and show that RelB exerts its anti-proliferative and anti-tumoral activities by functional activation of p53.
RESULTS

RelB slows down cell proliferation in murine fibroblasts
Although, as we previously reported, there is a significant basal level of RelB in the nucleus of primary murine embryonic fibroblasts (MEFs), 28 we wondered whether RelB might exert a biological activity in the absence of cell stimulation. To address the effect of RelB on cell growth in primary MEFs, we first used RNA interference (RNAi) to downregulate RelB levels, and analyzed the effect of RelB knockdown on three independent WT MEFs from different mice. As shown in Figure 1a , two different siRNAs (siRNA RelB no. 1 and siRNA RelB no. 2) directed against RelB efficiently repressed RelB protein levels; and most importantly, the growth rate of all three WT MEFs was markedly increased by RelB knockdown compared with that seen with the scrambled control siRNA. To extend the above observations, we next infected three independent WT MEFs with either an empty lentivirus or a lentivirus carrying RelB and analyzed cell growth. Ectopic expression of RelB in WT MEFs resulted in a marked reduction of cell growth ( Figure 1b) . As we have previously reported a crossregulation between RelA and RelB, 28 we also examined whether the increase in cell proliferation upon RelB knockdown observed in WT MEFs can still be seen in RelA-deficient MEFs. We found that RelA is not required for RelB to exert its anti-proliferative activity in fibroblasts (Supplementary Figure 1A) . In addition, p100 processing into p52 being a key step in the control of RelB activation, 29 we also analyzed cell growth in NF-kB2-deficient MEFs upon RelB knockdown, and showed that p100/p52 are not required for RelB to slow down cell proliferation in murine fibroblasts (Supplementary Figure 1B) .
To gain further insight into the mechanisms through which RelB slows down cell growth in fibroblasts, we next examined the effect of RelB on cell cycle progression. We first infected three Figure 1d ). Reciprocally, a reduced proportion of cells in G1 phase was observed upon RelB knockdown in WT MEFs (mean: 41 versus 29%) (Figure 1c , right, and Figure 1d ). These differences were statistically significant (P ¼ 0.0179 and P ¼ 0.0334, respectively). Importantly, apoptosis was not observed upon either RelB knockdown or ectopic expression, where no apoptotic peaks were detected, a finding that was further confirmed by annexin V/ propidium iodide staining (Supplementary Figure 2) . Collectively, our data indicate that RelB acts as a negative modulator of cell proliferation in fibroblasts and has a role in inducing a delay in the G1/S-phase transition.
RelB limits tumor growth in vivo As RelB can inhibit cell proliferation in WT MEFs, we speculated that RelB might also affect cell growth in transformed murine fibroblasts and consequently tumor growth in vivo. To test this hypothesis, we used NIH-3T3 cells transformed by the RET oncoprotein (NIH3T3/RET), described as forming tumors within days post-injection into immunodeficient mice, 30 infected these cells with either a lentivirus carrying a shRNA targeting RelB or a scrambled control and first analyzed cell growth. RelB knockdown in NIH3T3/RET cells resulted in a marked increase of cell growth (Figure 2a) , just as what was seen in primary MEFs. We next asked whether the growth-suppressive effect of RelB could consequently be seen on tumor growth in vivo. To test this hypothesis, we injected the NIH3T3/RET infected with a shRNA targeting RelB or a scrambled control into the flank of immunodeficient NOD-SCID mice, and followed tumor development over time. As shown in Figure 2b , RelB knockdown significantly promoted tumor growth in NOD-SCID mice. Conversely, RelB overexpression in NIH3T3/RET cells delayed tumor growth (Figure 2c ). Taken together, these data indicate that RelB can inhibit cell growth in non-transformed and transformed fibroblasts, and, as a result, limit tumor growth in vivo.
p53 is a RelB target gene in murine fibroblasts Given that p53 is a first-line tumor suppressor associated with cell growth arrest, 24, 25 we speculated that RelB might control p53 activation in fibroblasts. To test this hypothesis, we asked whether the forced expression of RelB in WT MEFs leads to the accumulation of p53 protein. As shown in Figure 3a , the amount of p53 protein was markedly and significantly elevated in WT MEFs infected with a lentivirus carrying RelB compared with what is seen in the empty virus-infected cells. Reciprocally, RelB knockdown by RNAi in WT MEFs decreased p53 protein expression levels ( Figure 3b) . Surprisingly, the cells exhibited no significant differences in the half-life of p53 protein and no interaction between RelB and p53 was observed, suggesting that RelB might instead regulate basal p53 expression at the transcriptional level in fibroblasts. To test this possibility, using quantitative RT-PCR, we first compared p53 mRNA levels in WT MEFs infected with either an empty lentivirus or a lentivirus carrying RelB. Ectopic expression of RelB in WT MEFs resulted in an increase in p53 mRNA levels (Po0.0001). In contrast, as a control, no significant effects on RelA expression were seen ( Figure 3c ). Reciprocally, RelB knockdown significantly decreased p53 mRNA levels ( Figure 3d , P ¼ 0.0004). Further, in vivo evidence for a direct role for RelB in regulating p53 transcription in WT MEFs was obtained by chromatin immunoprecipitation (ChIP) analysis. As shown in Figure 3e , RelB was found to be constitutively associated to the p53 promoter (Po0.0001). In contrast, no significant binding of RelA was observed. As controls neither RelB nor RelA were found to constitutively bind to the RANTES promoter, although TNFa stimulation induced efficient recruitment of RelA (Figure 3e ). Importantly, RelB recruitment was further increased upon RelB overexpression in WT MEFs (Figure 3f , Po0.0001). Taken together, these results indicate that RelB regulates p53 expression through direct transcriptional control in fibroblasts.
RelB regulates constitutive and inducible p53 activity Beyond controlling the transcription of the p53 tumor suppressor through direct recruitment to the p53 promoter, we investigated whether modulation of RelB levels also affected p53 activity. As several reports have indicated that p53 contributes towards basal expression of many of its target genes in untreated cells, 31, 32 we first examined by quantitative RT-PCR the effect of RelB knockdown on the mRNA levels of p21, Mdm2 and Gadd45b, which are known direct p53 transcriptional targets 24 in WT MEFs. As shown in Figure 4a , depletion of RelB resulted in a significant reduction in the expression of all three genes (P ¼ 0.0004, P ¼ 0.0008 and P ¼ 0.0230, respectively). To extend the above observations, we also analyzed the mRNA expression levels of these genes upon RelB overexpression in WT MEFs (Figure 4b ). Reintroduction of RelB induces an increase in p21, Mdm2 and Gadd45b mRNA levels (Po0.0001, P ¼ 0.0335 and P ¼ 0.0021, respectively). Importantly, RelB was not seen to bind to the p21, Mdm2 and Gadd45b promoters (Figure 4c ). To directly assess whether RelB regulation of p21 expression was p53 dependent, we compared p21 mRNA levels upon RelB ectopic expression in MEF p53
þ / þ and MEF p53 À / À . Significantly, p21 induction induced by RelB overexpression was lost in the absence of p53 (Figure 4d ), confirming that RelB is a p53-dependent positive regulator of p21 expression.
Next, we examined whether RelB also regulates inducible p53 function. The doxorubicin-induced increase in p53 protein was markedly reduced following shRNA-mediated knockdown of RelB in WT MEFs (Figure 4e) . A reduction in p53 serine 15 phosphorylation was also observed. Remarkably, loss of RelB resulted in reduced expression of p21 and Mdm2 in response to doxorubicin both at the mRNA (Figure 4f , upper panel) and protein levels (Figure 4f, lower panel) , thus indicating that RelB also contributes to p53 activation in response to DNA damage. In addition, RelB knockdown impaired p53 upregulation upon TNFR and LTbR ligation (Supplementary Figure 3) . Thus, basal and induced p53 activation is under the control of RelB.
Taken together, these results indicate that RelB is required for p53-dependent gene expression in fibroblasts. Figure 1a ). In contrast, no change in cell growth was observed when RelB expression was inhibited in MEF p53
RelB inhibits
À / À cells (Figure 5a , center), indicating that RelB promotes p53-mediated cell growth arrest. Importantly, RelB knockdown in MEF p53
resulted in a decrease in basal expression of p53 (Figure 5a, right) .
As p53 has significant roles in the regulation of tumor progression, 24 we speculated that RelB might exert its negative effect on tumor growth through its control of p53 activity. To test this hypothesis, we examined the effect of forced expression of p53 on the tumorigenesis seen when NIH-3T3/RET cells stably e.m. of three independent experiments using three independent WT MEFs normalized to the level HPRT mRNA, ***Po0.001. (e) RelB is constitutively bound to the p53 promoter in WT MEFs. Recruitment of RelA and RelB to the p53 and RANTES promoters was examined in two independent WT MEFs by ChIP experiments followed by quantitative PCR analysis. Two independent WT MEFs were left untreated or treated with TNF-a for 1 h and recruitment of RelB to the p53 and Rantes promoters was examined by ChIP experiments followed by quantitative PCR analysis. Results are means ± s.e.m. of three independent experiments, n ¼ 2, normalized to inputs that reflect relative amount of sonicated DNA fragments present before immunoprecipitation, ***Po0.001. (f) Recruitment of RelB to the p53 promoter is increased upon RelB ectopic expression. Recruitment of RelB to the p53 and RANTES promoters was examined in two independent WT MEFs stably transduced with lentiviruses encoding either the parental empty vector (control) or RelB as described in (e), ***Po0.001.
transduced with lentiviruses carrying either a shRNA targeting RelB (shRNA RelB) or a scrambled control (shRNA control) were injected into NOD-SCID mice. Overexpression of p53 counteracted the increase in tumor progression observed upon RelB knockdown, whereas it had no significant effect on the tumor growth observed upon expression of the scrambled control sequence (Figure 5b ). Taken together, our results suggest that RelB promotes cell cycle arrest and inhibits tumor growth in a p53-dependent manner.
DISCUSSION
In the present study, we uncovered a role for RelB in limiting cell proliferation and tumor growth in vivo. On the other hand, in numerous experimental systems, unequivocal evidence indicates that NF-kB promotes cell growth and tumorigenesis. [4] [5] [6] Thus, the data presented here are somewhat provocative with respect to the generally accepted role of NF-kB in the development of human cancers. Furthermore, our findings point to a mechanism involving direct transcriptional activation of the p53 tumorsuppressor gene by RelB. Although there is accumulating evidence linking IKK/NF-kB to the p53 pathway, [15] [16] [17] 26, 27 a direct role for RelB as a regulator of p53 expression and activity was not defined previously.
ChIP experiments have shown that RelB is recruited to the region that encompasses the NF-kB-binding sequence of the p53 promoter in fibroblasts. 33, 34 These data are consistent with the suggested kB site serving as a functional NF-kB subunit-binding site. 33 However, RelA recruitment to the p53 promoter was not significantly seen under the same conditions, suggesting that these effects might be specific to RelB in fibroblasts. As we have shown that RelB exerts its anti-proliferative activity independently of RelA, our data suggest that the anti-proliferative and antitumoral activities of RelB are exerted through kB site-and DNAbinding-dependent recruitment of RelB to the p53 promoter. However, it would be simplistic to attribute all of these negative effects on cell growth to the control of p53 expression and function, and RelB may additionally modulate cellular responses via other target genes that remain to be identified.
In contrast to our findings, it has been recently reported that basal p53 expression is under direct RelA-dependent transcriptional control in MEFs. 35 The reasons for these discrepant results are not clear but could be due to differences in conditions employed for the ChIP analysis. Interestingly, it was shown that p53 is a crucial downstream mediator of RelA in the bioenergetics pathway controlling adaptation to metabolic stress. 35 Whether RelB might be involved in the control of adaptation to metabolic stress by controlling p53 expression is worth further investigation.
The cross-regulation between RelB and p53 that we report here is likely to be part of a wider complex network intimately linking p53 and the alternative NF-kB pathway. This pathway controls the activation of RelB-containing dimers (that is, RelB-p52 and RelBp50) and relies on the inducible activation of IKKa in response to a specific subset of stimuli. 29 For example, IKKa-mediated phosphorylation of the CBP transcriptional co-activator increases cell proliferation by inhibiting the binding of CBP to p53, while promoting the interaction with RelA. 36 In several cell lines, p52 is directly recruited by p53 to multiple p53-regulated promoters where it regulates co-activator or co-repressor recruitment, thus leading to either repression or activation of p53 target genes associated with cycle arrest and cell death. 37, 38 However, p52 has no significant effects on p53 expression levels, 37 indicating that the effects we have observed with RelB are distinct from those described for p52 in human cancer cells. Although establishment of the significance of these observations will require further investigation, they nevertheless underline the complex relationships that exist between NF-kB and p53.
We have found that RelB slows down cell proliferation and tumor growth in fibroblasts. It has been recently reported that RelB can promote the more invasive phenotype of ERa-negative breast cancer cell lines, 22 and RelB knockdown reduces the size of primary prostate carcinomas in a mice xenograft tumor model, 23 while RelB can act as a negative regulator of cell survival in diffuse large B-cell lymphoma cell lines characterized by constitutive Malt1 activity. 39 Thus, whether RelB is a tumor suppressor or a tumor promoter is most likely context dependent, which is worth further investigation.
It is firmly established that NF-kB activation is associated with cell proliferation through the induction of pro-proliferative genes. 1, 6 More recently, the relevance of NF-kB for tumor maintenance, tumor development and even possibly tumor initiation is becoming evident. 5, 6, 7 Thus, without calling into question this paradigm as a whole, our data support an alternative mechanism: a likely role for RelB in limiting cell proliferation and tumor growth. A similar conclusion was made earlier from studies of RelA-deficient epidermal cells, showing that NF-kB antagonized proliferative signals derived from TNFR and JNK. 40 In human keratinocytes, NF-kB triggers cell cycle arrest and blockade of NF-kB generates malignant human epidermal tissue resembling squamous cell carcinoma (SCC). 10 Similarly, loss of IKKa causes striking epidermal hyperplasia in mice, 41 and reduction in IKKa expression promotes skin carcinogenesis in mice. 42 Most importantly, loss of heterozygosity, as well as genetic and epigenetic alterations of the IKKa locus have been reported in SCC of the skin, esophagus, and head and neck in humans, 43, 44 indicating a novel role of IKKa as a tumor suppressor in SCC. Another striking example of the counterintuitive role of NF-kB in limiting cell growth has been provided by analysis of IKKbdeficient MEFs, 11 and a study using mice with a hepatocytespecific deletion in the IKKb gene demonstrated that hepatocytespecific IKKb deficiency promotes chemical carcinogen-induced hepatocarcinogenesis. 12 Therefore, a careful re-evaluation is certainly required to define the role of NF-kB in the various stages of malignant transformation and tumorigenesis, and re-introducing the tumor suppressor form of NF-kB might have great potential for therapeutic intervention.
In conclusion, we established RelB as an important p53-positive regulator that exerts its inhibitory role on cell growth and tumorigenesis in a p53-dependent manner. Our data are of great functional importance because they constitute a significant advance in the understanding on RelB physiological function and shed light on a novel positive link between NF-kB and growth-inhibitory pathways.
MATERIALS AND METHODS
Antibodies and reagents
The antibodies were purchased from Santa Cruz Biotechnology, Santa Cruz, CA, USA (RelA C-20, RelB C-19, p53 FL-393) and Sigma-Aldrich, St Louis, MO, USA (b-actin, clone AC-15). Doxorubicin and murine TNF-a were purchased from Sigma-Aldrich, and agonistic anti-LTbR mAb AC.H6 was a kind gift from J Browning.
Plasmids
Expression vectors for RelB was obtained from M Kö rner (Institut André Lwoff, Villejuif, France), p53 from K Vousden (the Beatson Institute for Cancer Research, Glasgow, UK), M Oren (the Weizmann Institute of Science, Rehovot, Israel) and D Reisman (University of South Carolina, Columbia, SC, USA), and pSuper vector-containing polymerase III H1 promoter was provided by T Tuschl (the Rockfeller University, New York, NY, USA). pTripshRNA RelB was generated by subcloning an oligonucleotide designed to target RelB under control of the H1 promoter into pTRIP-DU3-MND-GFP lentiviral vector. 45 pTRIP-shRNA control was generated following the same approach using a scrambled control oligonucleotide. RelB sense 5'-GATCCCCGGAAATCATCGACGAATACTTCAAGAGAGTATTCGTCGATGATTTCC TTTTTGAATTCA-3 0 ; RelB antisense 5 0 -AGCTTGAATTCAAAAAGGAAATCATC RelB inhibits cell proliferation through p53 E Jacque et al
0 . pTrip-RelB and pTRIP p53 were generated by subcloning, into pTRIP-DU3-EF1a-IRES GFP lentiviral vector, 45 full-length RelB and p53 cDNA, respectively.
Cell culture
RelB À / À mouse embryonic fibroblasts (MEFs) were kind gifts from F Weih (Fritz Lipmann Institute, Jena, Germany), p53
þ / þ and p53 À / À MEFs from T Jacks (MIT, Cambridge, USA), NIH-3T3/RET from B Tavitian (CEA Saclay, Saclay, France), and NF-kB2 þ / þ and NF-kB2 À / À from F Weih and U Siebenlist (the National Institute of Allergy and Infectious Diseases, Bethesda, MD, USA). Cells were grown in Dulbecco's modified Eagle medium (Life Technologies, Grand Island, NY, USA) supplemented with 10% heat-inactivated fetal bovine serum, 2 mM L-glutamine, 1 mM sodium pyruvate and 100 units/ml penicillin-streptomycin.
Lentiviral production and transduction
Production of infectious recombinant lentiviruses was performed by transient transfection of 293 T cells as described in Kieusseian et al. 45 PSer15-p53
α-RelB
RelB inhibits cell proliferation through p53 E Jacque et al p24 (HIV-1 capsid protein). Fourty-eight hours later, cells were washed and fresh medium was added. The culture was then continued as described above. GFP-positive cells were sorted with Cytopea Influx-500 sorter (BD Biosciences, San Jose, CA, USA).
siRNA transfections siRNA transfections were performed as described previously. 28 All siRNA duplex oligonucleotides targeting the following proteins were synthesized by Proligo: RelB no. 1 sense 5 0 -GGAAAUCAUCGACGAAUACdTdT-3 0 ; RelB no. 2 sense 5 0 -UCAUCACAGAGCAGCCAAAdTdT-3 0 ; scrambled control sense 5 0 -CGUACGCGGAAUACUUCGAdTdT-3'.
Immunoblotting
Immunoblotting were performed as described in Jacque et al.
28
Real time RT-PCR Total RNA extraction and RT were performed as previously described. 
ChIP assays
ChIP assays were performed as described. 28 Samples were analyzed by real-time PCR. Sequences of promoter-specific primers are as follow: p53 sense 5 0 -TTGCCCTTACTTGTTATG-3 0 ; p53 antisense 5 0 -CCCAATGAACTG AAGCTACAG-3 0 ; MCP1 sense TCCAATACTGCCTCAGAATGG; and MCP1 antisense ATCACCATTGCAAAGTGAATTG.
Cell proliferation assays
Cells (1500/well) were seeded in 96-well plates and grown under the culture conditions as described above. Cell viability was assessed every 
